Még nem keres résztvevőt itt: Egyesült Államok1. fázis
Lorlatinib Plus TNG462 in ALK+ MTAP Del NSCLC
A legfontosabb adatok
- Ki végzi
- Dana-Farber Cancer Institute
- Hol
- Boston (Egyesült Államok)Mind a 2 helyszín megnézése
- Azonosító
- Állapot
- Toborzás még nem indult
- Fázis
- 1. fázis
- Résztvevők
- 30 fő, tervezett
- Kezdés
- 2027. ápr. 30.
- Várható befejezés
- 2028. jún. 30.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- TNG462 vopimetostat
- Lorlatinib
- A regiszteradat frissítve
- 2026. november 16.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 31 feltétel megnézéseKevesebb
Ki vehet részt
- Age ≥ 18 years
- Histologically or cytologically confirmed NSCLC harboring an ALK rearrangement, documented by an FDA/EMA-approved or validated local test
- Confirmed MTAP loss, demonstrated by immunohistochemistry (IHC) as complete loss in the presence of a positive internal control, or homozygous deletion by next-generation sequencing (NGS) in a CLIA-/ISO-accredited laboratory. The Sponsor-Investigator will review molecular testing to confirm eligibility (central reading of the IHC sample and/or repeat MTAP staining on archival tissue; check of the NGS report). Cases with heterogenous MTAP loss in IHC defined as MTAP loss in at least 80% of the tumor cells but less than 100%, may be included with the permission of the Sponsor-Investigator and after central revision of the slides
- Radiographic disease progression after at least one or more ALK TKIs, including prior lorlatinib therapy. Prior chemotherapy and prior neladalkib (NVL-655) are allowed
- At least one measurable extracranial lesion according to RECIST v1.1
- ECOG performance status 0-1 (Appendix A). ECOG performance status 2 may be allowed with the permission of the Sponsor-Investigator
- Adequate organ and marrow function, defined as:; ANC ≥ 1.5 × 10⁹/L; Platelets ≥ 75 × 10⁹/L, without platelet transfusion within 7 days prior to screening hematology assessment; Hemoglobin > 8.5 g/dL without transfusion within 14 days prior to screening hematology assessment; AST/ALT ≤ 2.5 × ULN (≤ 5 × ULN with documented liver metastases); Total bilirubin ≤ 1.5 × ULN; Creatinine clearance ≥ 45 mL/min
- Stable, previously treated brain metastases permitted if neurologically stable ≥ 2 weeks and on ≤ 10 mg prednisone equivalent. Untreated CNS metastases may be permitted with PI approval if: lesions are asymptomatic, ≤5 mm in size, no radiologic evidence of surrounding edema, and no current or anticipated need for corticosteroids
- Life expectancy ≥ 12 weeks
- Ability to swallow oral medication. TNG 462 tablets may be crushed and administered via NG-G tube if necessary, with written approval from Principal Investigator. Lorlatinib may not be crushed
- Written informed consent obtained prior to study procedures
- Participants must understand, sign and date the written informed consent form prior to any protocol-specific procedures performed. Participants should be able and willing to comply with study visits and procedures as per protocol
Ki nem vehet részt
- Leptomeningeal carcinomatosis or spinal cord compression unless treated, clinically stable ≥ 4 weeks, and off steroids ≥ 14 days
- History of myocardial infarction, unstable angina, coronary revascularization, stroke, or transient ischemic attack (TIA) within 6 months before C1D1
- Interstitial lung disease, organizing pneumonia, or drug-induced pneumonitis, including prior lorlatinib-related pneumonitis, unless completely resolved
- Active uncontrolled infection requiring intravenous therapy within 7 days before C1D1
- Any other active malignancy within 2 years prior to enrollment, except adequately treated basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, early-stage prostate cancer undergoing active surveillance, curatively treated thyroid cancer, early stage breast cancer or DCIS, or any in situ cancers that have been treated with curative intent
- Has any of the following: prior history of drug-induced or toxic retinopathy, or optic neuropathy; uncontrolled glaucoma; pre-existing macular degeneration; ongoing Grade ≥3 retinopathy, optic neuropathy, or optic neuritis; or any other known active retinal pathology
- History of seizure disorder requiring enzyme-inducing antiepileptic drugs that cannot be substituted
- Symptomatic congestive heart failure (NYHA ≥ Class II) or uncontrolled hypertension despite optimal medical therapy
- Known HBsAg-positive or HCV RNA-positive infection with detectable viral load. Participant on suppressive antiviral therapy with undetectable viremia are eligible
- HIV infection with CD4 < 200/μL or on antiretrovirals that are strong CYP3A modulators
- Clinically significant gastrointestinal disorder that may affect absorption of oral medications (e.g., malabsorption syndrome, chronic diarrhea, short-bowel syndrome)
- Clinically significant neurocognitive disorder, mood alteration, or psychiatric illness (including major depression or psychosis) that, in the investigator's judgment, could be exacerbated by lorlatinib or impair adherence
- Known hypersensitivity to TNG462, lorlatinib, or any of their excipients
- 3.2.1 Prior treatment with a PRMT5 inhibitor, MAT2A inhibitor, or any investigational agent targeting the same pathway; 3.2.2 Prior treatment with lorlatinib resulting in discontinuation due to ≥ Grade 3 toxicity or with unresolved ≥ Grade 2 neurocognitive, pulmonary, or psychiatric adverse events at screening; 3.2.3 Ongoing or unresolved toxicity > Grade 1 from previous anticancer therapy (per CTCAE v5.0), except for the following: alopecia, endocrinopathies controlled by replacement therapy, or other protocol-allowed persistent Grade 2 toxicities (e.g., neuropathy) that, in the investigator's judgment, do not pose an unacceptable safety risk; 3.2.4 Major surgery within 4 weeks before first dose or incomplete recovery from surgery; 3.2.5 Radiotherapy within 2 weeks before C1D1 (≤ 1 week for palliative RT ≤ 2 Gy/fraction); prior cranial RT permitted if completed ≥ 2 weeks before C1D1 and participant neurologically stable; 3.2.6 Concomitant use of strong or moderate CYP3A inhibitors or inducers, CYP3A or P-gp substrates with a narrow therapeutic index (e.g., digoxin, cyclosporine), or OATP1B3 substrates with a narrow therapeutic index (e.g. rosuvastatin, methotrexate, sirolimus), that cannot be discontinued or replaced; 3.2.7 Use of medications known to prolong QTc > 480 ms that cannot be safely discontinued
- Baseline QTc > 480 ms (Fridericia), PR > 220 ms, clinically significant atrioventricular (AV) block, or uncontrolled arrhythmia
- Uncontrolled hyperlipidemia defined as fasting total cholesterol > 300 mg/dL or triglycerides > 300 mg/dL despite medical management
- Pregnancy or breastfeeding. Women of childbearing potential must have a negative serum pregnancy test within 7 days before first dose and agree to use two highly effective contraceptive methods during treatment and for ≥ 6 months after the last dose. Male participants must use effective contraception for ≥ 3 months after the last dose
- Any condition (medical, psychiatric, social, or laboratory abnormality) that, in the opinion of the investigator, may confound study results, increase risk, or interfere with study compliance
- Participants who, in the investigator's or Sponsor-Investigator's judgment, are unable to comply with protocol requirements or whose participation would not be in their best interest may be excluded
Helyszínek itt: Egyesült Államok
- Brigham and Women's HospitalBoston, Egyesült ÁllamokContact: Alice Shaw, MD, PhDToborzás még nem indult
- Dana-Farber Cancer InstituteBoston, Egyesült ÁllamokContact: Alice Shaw, MD, PhDToborzás még nem indult
A vizsgálatról
Mit akar kideríteni a vizsgálat
TAP-ALK is a DF/HCC investigator-sponsored interventional study of TNG462 (vopimetostat) in combination with lorlatinib for participants with MTAP-deleted, ALK-rearranged non-small cell lung cancer (NSCLC) following progression on prior tyrosine kinase inhibitor (TKI) therapy. The study is being conducted under IND 183798 and plans to enroll 30 participants.
A vizsgálat csoportja
- TNG462 plus LorlatinibA vizsgált kezelés
Participants receive TNG462 once daily and lorlatinib once daily according to the study treatment plan and study calendar.
Kezelés: TNG462 vopimetostat és Lorlatinib
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- TAP-ALK: A Phase I/II Study of TNG462 in Combination With Lorlatinib in MTAP-Deleted, ALK-Rearranged NSCLC Following Progression on Prior TKI Therapy
- A regiszteradat frissítve
- 2026. november 16.